Group 1 - The company Huangshan Capsule announced the convening of its fifth board meeting on August 22, 2025, to review the 2025 semi-annual report and its summary [2] - The meeting was held in a combination of on-site and communication methods [2] - The announcement was reported by the Daily Economic News [2] Group 2 - The company is preparing to disclose its financial performance for the first half of 2025 [2] - The board meeting is a key event for stakeholders to assess the company's financial health and strategic direction [2] - The report will likely include important metrics and insights into the company's operations and market position [2]

安徽黄山胶囊股份有限公司 2025 年半年度报告全文 安徽黄山胶囊股份有限公司 2025 年半年度财务报告 【2025 年 8 月】 1 安徽黄山胶囊股份有限公司 2025 年半年度报告全文 第一节 财务报告 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的单位为：元 1、合并资产负债表 编制单位：安徽黄山胶囊股份有限公司 2025 年 06 月 30 日 单位：元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 291,927,945.73 | 341,642,031.24 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | | | | 衍生金融资产 | | | | 应收票据 | 266,532.00 | 3,332,429.00 | | 应收账款 | 134,425,432.83 | 110,369,995.29 | | 应收款项融资 | 41,461,881.46 | 28,057,573.29 | | 预付款项 | 167,069.0 ...

编制单位：安徽黄山胶囊股份有限公司 安徽黄山胶囊股份有限公司2025年半年度非经营性资金占用及其他关联资金往来情况汇总表 单位：万元 公司负责人: 李合军 主管会计工作的负责人: 刘清科 会计机构负责人: 褚洪欢 3 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公 | 上市公司核算 | 2025年期初占 | 2025年半年度 占用累计发生 | 2025年半年 度占用资金 | 2025年半年度 偿还累计发生 | 2025年半年度 期末占用资金 | 占用形成原 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 司的关联关系 | 的会计科目 | 用资金余额 | 金额（不含利 | 的利息（如 | | | 因 | 占用性质 | | | | | | | 息） | 有） | 金额 | 余额 | | | | 控股股东、实际控制人及其附属企业 | | | | | | | | - | | | | | | | | | | | | - | | | | 小计 | - | - | - | - | - | - | - | ...

Core Viewpoint - Huangshan Capsule (002817.SZ) reported a revenue of 244 million yuan for the first half of 2025, reflecting a year-on-year growth of 3.66% [1] - The net profit attributable to shareholders reached 35.55 million yuan, marking a year-on-year increase of 19.78% [1] - The net profit excluding non-recurring gains and losses was 34.39 million yuan, showing a year-on-year growth of 23.53% [1] - Basic earnings per share stood at 0.12 yuan [1] Financial Performance - Revenue for the first half of 2025: 244 million yuan, up 3.66% year-on-year [1] - Net profit attributable to shareholders: 35.55 million yuan, up 19.78% year-on-year [1] - Net profit excluding non-recurring items: 34.39 million yuan, up 23.53% year-on-year [1] - Basic earnings per share: 0.12 yuan [1]

证券代码：002817 证券简称：黄山胶囊 公告编号：2025-020 安徽黄山胶囊股份有限公司 经审核，监事会认为：公司 2025 年半年度报告及其摘要的编制和审议程序 符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了 公司的财务状况和经营成果，不存在任何虚假记载、误导性陈述或者重大遗漏。 《公司 2025 年半年度报告》《2025 年半年度报告摘要》详见公司指定信息 披 露 媒 体 《 证 券 时 报 》《 上 海 证 券 报 》《 中 国 证 券 报 》 和 巨 潮 资 讯 网 （http://www.cninfo.com.cn）。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 三、备查文件 1. 第五届监事会第十三次会议决议。 安徽黄山胶囊股份有限公司（以下简称"公司"）第五届监事会第十三次会 议（以下简称"本次会议"）通知于 2025 年 8 月 15 日以电话、电子邮件等方式 发出，并于 2025 年 8 月 22 日在公司一楼会议室以现场结合通讯的方式召开。本 次会议由监事会主席张新华先生主持，部分高级管理人员列席了会议，本次会议 应到监事 3 名，实到监事 3 名 ...

证券代码：002817 证券简称：黄山胶囊 公告编号：2025-019 安徽黄山胶囊股份有限公司 第五届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 安徽黄山胶囊股份有限公司（以下简称"公司"）第五届董事会第十三次会 议（以下简称"本次会议"）的通知已于 2025 年 8 月 15 日以电话、电子邮件等 方式向全体董事发出。本次会议于 2025 年 8 月 22 日在公司一楼会议室以现场结 合通讯方式召开，应到董事 7 名，实到董事 7 名，其中王清华女士以通讯表决方 式出席。本次会议由董事长李合军先生主持，公司监事和高级管理人员列席了会 议。本次会议的通知、召集、召开、审议、表决程序均符合有关法律、行政法规、 规范性文件和《公司章程》的规定，会议形成的决议合法、有效。 二、董事会会议审议情况 1. 第五届董事会第十三次会议决议； 1. 审议通过《公司 2025 年半年度报告及其摘要》 《公司 2025 年半年度报告》《2025 年半年度报告摘要》详见公司指定信息 披 露 媒 体 《 证 券 时 报 》《 ...

Financial Performance - The company's operating revenue for the first half of 2025 was ¥243,881,502.87, representing a 3.66% increase compared to ¥235,268,376.00 in the same period last year[22]. - The net profit attributable to shareholders was ¥35,552,521.32, a 19.78% increase from ¥29,682,423.79 year-on-year[22]. - The net profit after deducting non-recurring gains and losses was ¥34,398,836.32, up 23.53% from ¥27,847,641.38 in the previous year[22]. - The basic earnings per share rose to ¥0.12, a 20.00% increase from ¥0.10 in the previous year[22]. - The company achieved operating revenue of 243.88 million yuan, an increase of 3.66% compared to the previous year[36]. - Net profit attributable to shareholders reached 35.55 million yuan, reflecting a growth of 19.78% year-over-year[36]. - The company's revenue for the reporting period was ¥243,881,502.87, representing a year-on-year increase of 3.66% compared to ¥235,268,376.00 from the previous year[45]. - The company achieved a net cash flow from operating activities of ¥29,102,797.29, a significant increase of 355.30% from a negative cash flow of ¥11,399,312.29 in the previous year[45]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,109,638,569.04, reflecting a 2.13% increase from ¥1,086,534,605.98 at the end of the previous year[22]. - The net assets attributable to shareholders increased by 2.64% to ¥940,599,777.94 from ¥916,439,508.41 at the end of the previous year[22]. - The company’s cash and cash equivalents decreased to ¥291,927,945.73, accounting for 26.31% of total assets, down from 31.44% the previous year[49]. - Total current assets decreased from ¥590,012,632.85 to ¥568,315,561.21, indicating a decline of about 3.7%[107]. - Total liabilities decreased to ¥167,484,316.97 from ¥168,773,049.88, reflecting a decline of about 0.8%[109]. - Owner's equity increased to ¥942,154,252.07 from ¥917,761,556.10, marking an increase of approximately 2.6%[109]. Market and Competition - The company is facing increased competition in the hollow capsule market due to anti-dumping and countervailing duties imposed by the U.S., with a comprehensive tax rate of 136.14% applicable to its exports[30]. - The revenue proportion of enteric-coated gelatin capsules and plant-based capsules increased from 26.17% to 35.46% compared to the same period last year[36]. - The company focuses on high-end market development and has improved its product structure significantly[36]. - The company plans to enhance its production capabilities in high-end pharmaceutical excipients, aligning with national industrial guidance[30]. Research and Development - The R&D investment for the reporting period was ¥6,063,998.06, which is a decrease of 9.10% compared to ¥6,670,795.43 in the previous year[45]. - The company has developed core technologies in enteric coating materials and has received multiple invention and design patents[40]. - The company plans to invest 100 million yuan in research and development for new technologies in the upcoming year[129]. - Research and development expenses have increased by 15% compared to the previous year, reflecting the company's commitment to innovation[135]. Cash Flow and Financing - Operating cash flow for the first half of 2025 was ¥29,102,797.29, a significant improvement compared to a negative cash flow of ¥11,399,312.29 in the first half of 2024, indicating a turnaround in operational efficiency[121]. - The company reported a net cash outflow from financing activities of ¥19,765,380.37 in the first half of 2025, compared to a larger outflow of ¥26,687,739.70 in the first half of 2024, showing a reduction of about 26%[122]. - The total cash inflow from investment activities in the first half of 2025 was ¥54,901,664.40, significantly higher than ¥11,108,076.00 in the first half of 2024, marking an increase of approximately 393%[122]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 17,906[96]. - Shandong Lutai Holding Group Co., Ltd. holds 29.99% of shares, totaling 89,699,541 shares[96]. - The total number of shares before the recent change was 299,098,170, with the same number after the change[95]. - The proportion of limited sale condition shares remained at 3.03% after the change[94]. Future Outlook - Future outlook indicates a focus on expanding market presence, targeting a 10% increase in market share by the end of 2025[128]. - The company is considering potential acquisitions to enhance its product portfolio, with a budget of 200 million yuan allocated for this purpose[128]. - The overall capital expenditure for the year is projected to be 300 million yuan, focusing on production capacity enhancement[129]. - The company aims to improve operational efficiency by 5% through strategic cost management initiatives[130]. Compliance and Governance - The financial statements have been prepared in accordance with the relevant accounting standards, ensuring transparency and compliance with regulatory requirements[145]. - The company has not identified any significant doubts regarding its ability to continue as a going concern for the next 12 months, ensuring stability for stakeholders[143]. - There were no significant legal disputes or penalties during the reporting period[75][76].

Company Overview - Huangshan Capsule Co., Ltd. specializes in the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules, being one of the earliest manufacturers in China with over thirty years of high-quality production history [1][2] - The company has a strong reputation in the pharmaceutical hollow capsule industry and is a member of the China Pharmaceutical Packaging Association, recognized for its contributions [1] Financial Performance - For Q1 2025, the company reported revenue of 119 million yuan, a year-on-year increase of 0.53%, and a net profit of 18.837 million yuan, reflecting a year-on-year growth of 22.90% [2] - The sales gross margin for the same period was 29.26% [2] Market Position - As of August 19, the company's stock closed at 8.06 yuan, with a PE ratio of 45.69, compared to the industry average of 59.49 and the industry median of 40.19 [1][2] - The total market capitalization of Huangshan Capsule is 2.411 billion yuan [1] Shareholder Information - As of March 31, 2025, the number of shareholders is 18,378, a decrease of 26 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]

Core Insights - Huangshan Capsule's stock closed at 8.18 yuan, up 1.11%, with a rolling PE ratio of 46.37 times and a total market capitalization of 2.447 billion yuan [1] - The company operates in the medical device industry, which has an average PE ratio of 55.70 times and a median of 39.08 times, placing Huangshan Capsule at the 84th position in the industry ranking [1] - As of the first quarter of 2025, only one institution holds shares in Huangshan Capsule, with a total of 18,000 shares valued at 0.00 billion yuan [1] Company Overview - Anhui Huangshan Capsule Co., Ltd. specializes in the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules [1] - The company is one of the earliest manufacturers of medicinal hollow capsules in China, boasting over 30 years of high-quality production history [1] - Huangshan Capsule has a strong reputation in the medicinal hollow capsule industry and is a member of the China Pharmaceutical Packaging Association, recognized for its contributions [1] Financial Performance - In the first quarter of 2025, the company reported an operating income of 119 million yuan, a year-on-year increase of 0.53%, and a net profit of 18.837 million yuan, reflecting a year-on-year growth of 22.90% [2] - The sales gross margin for the company stands at 29.26% [2] Industry Comparison - Huangshan Capsule's PE (TTM) is 46.37, compared to the industry average of 55.70 and the industry median of 39.08 [2] - The company’s market capitalization is 2.447 billion yuan, while the industry average market capitalization is 11.731 billion yuan [2]

Core Insights - The report highlights the importance of CFOs in listed companies, with the total salary scale for CFOs in A-share companies reaching 4.27 billion yuan in 2024 [1] - The average annual salary for CFOs in the raw material pharmaceutical sector is 661,200 yuan [1] Salary Distribution - The top three highest-paid CFOs are Gong Yuda from Guobang Pharmaceutical with 1.93 million yuan, Li Qirong from Zhejiang Pharmaceutical with 1.84 million yuan, and Hou Ning from Xinhua Pharmaceutical with 1.57 million yuan [1] - The salary distribution shows that 44% of CFOs earn below 500,000 yuan, 44% earn between 500,000 and 1 million yuan, and 12% earn above 1 million yuan [1] Age and Education Distribution - CFOs aged 40-50 constitute the majority at 36%, while those aged 60 and above account for 5% [1] - The educational background of CFOs shows that 65% hold a bachelor's degree, 21% have a master's degree, and only 2% have a high school diploma [1] Salary Changes - Liu Qingke from Huangshan Capsule experienced the largest salary decrease at 19.04%, while Qian Dan from Nengte Technology saw the highest salary increase at 100.58% [1]